

Florenzo Iannone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7407815/publications.pdf>

Version: 2024-02-01

352
papers

9,796
citations

41344

49
h-index

62596

80
g-index

359
all docs

359
docs citations

359
times ranked

9471
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
2	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 475-480.	2.0	2
3	Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF). <i>Joint Bone Spine</i> , 2022, 89, 105259.	1.6	0
4	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	3.4	20
5	The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e145-e149.	0.9	10
6	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , 2022, 89, 105299.	1.6	4
7	Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMCCR immune-mediated necrotizing myopathy. <i>Rheumatology</i> , 2022, 61, 3448-3460.	1.9	9
8	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
9	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
10	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. <i>RMD Open</i> , 2022, 8, e001847.	3.8	19
11	Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2022, 49, 334-335.	2.0	9
12	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. <i>Ophthalmology and Therapy</i> , 2022, 11, 887-897.	2.3	9
13	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	2.2	7
14	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
15	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
16	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 353.	2.5	9
17	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	1.9	6
18	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. <i>Frontiers in Immunology</i> , 2022, 13, 860877.	4.8	9
20	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	1.9	7
21	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
22	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients with Rheumatoid Arthritis (the MITRA study). A cohort study of the I.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
23	Informed Consent and Biological Agents in Rheumatology and Internal Medicine. <i>European Journal of Clinical Investigation</i> , 2022, , e13805.	3.4	1
24	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
25	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the "JAK-pot"™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.9	48
26	Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1921-1928.	2.0	8
27	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.9	9
28	Development and implementation of the AIDA International Registry for patients with Behçet's™ disease. <i>Internal and Emergency Medicine</i> , 2022, 17, 1977-1986.	2.0	11
29	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, 2916-2926.	1.9	13
30	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	2.0	7
31	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
32	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13363.	3.4	6
33	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
34	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	3.0	14
35	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	1.9	41
36	Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. <i>Rheumatology</i> , 2021, 60, 1234-1242.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e73-e74.	0.9	3
38	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5
39	A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1457-1465.	2.0	23
40	Pulmonary arterial hypertension: guidelines and unmet clinical needs. <i>Reumatismo</i> , 2021, 72, 228-246.	0.9	10
41	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110371.	2.7	1
42	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021, Publish Ahead of Print, .	0.9	14
43	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , 2021, 16, 2163-2171.	2.0	8
44	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , 2021, 40, 3659-3665.	2.2	2
45	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
46	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	2.2	3
47	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
48	OP0220...SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 17453 BIO-NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING TNFI - RESULTS FROM THE EUROSPA COLLABORATION. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 131.2-132.	0.9	0
49	OP0310...GENDER AND FIBROMYALGIA SEVERITY: REAL LIFE DATA FROM THE ITALIAN REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 190-191.	0.9	0
50	POS0675...THE COMPARATIVE 3-YEAR RETENTION RATE OF TARGETED-SYNTHETIC AND BIOLOGIC DRUGS FOR RHEUMATOID ARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN GISEA REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 582.1-582.	0.9	1
51	POS1021...THE PsABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 778-779.	0.9	0
52	OP0093...RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER'S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 51-52.	0.9	1
53	Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 507-530.	2.0	10
54	POS0027...SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 27189 BIO-NAIVE AXIAL SPONDYLOARTHRITIS PATIENTS INITIATING TNFI - RESULTS FROM THE EUROSPA COLLABORATION. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 217-218.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.9	6
56	ABO716â€...FIBROMYALGIA SYNDROME SEVERITY ACCORDING TO AGE CATEGORIES: RESULTS FROM A NATIONAL REGISTER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1389.2-1390.	0.9	0
57	Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 625.	2.5	20
58	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1410-1418.	0.9	28
59	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 265-274.	4.9	31
60	Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. <i>Vaccines</i> , 2021, 9, 730.	4.4	27
61	Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 206, 153-160.	2.6	10
62	Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. <i>Frontiers in Medicine</i> , 2021, 8, 737079.	2.6	14
63	Management of Takayasu Arteritis Diagnosed During Pregnancy: A Case Report. <i>Archives of Rheumatology</i> , 2021, 36, 138-139.	0.9	0
64	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e122-e122.	0.9	2
65	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	3.8	4
66	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	8
67	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227.	0.8	1
68	Methotrexate in Italian patients with Rheumatoid Arthritis (MITRA study): an observational study about the use of methotrexate in early RA patients and the adherence to the EULAR 2013 recommendations. A project of the Italian Society for Rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1077-1084.	0.8	1
69	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1147-1148.	0.8	0
70	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2021, .	0.8	0
71	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227-227.	0.8	6
72	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Is retinal microvascular damage an early manifestation of systemic sclerosis?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e167-e167.	0.9	0
74	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e104-e104.	0.9	4
75	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 298-304.	1.8	46
76	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Trial. <i>Open Access Rheumatology: A Practical Approach</i> , 2020, 10, 956-964.	1.8	98
77	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1188-1188.	1.9	9
78	Response to: "Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro et al." by Agca et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e106-e106.	0.9	0
79	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 17-24.	3.4	19
80	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1599-1606.	1.9	24
81	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment" results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020, 59, 1640-1650.	1.9	18
82	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.8	75
83	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	1.9	25
84	Symmetrical Panniculitis in a Patient With Dermatomyositis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e311-e311.	0.9	1
85	Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13343.	3.4	2
86	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	3.5	7
87	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	3.8	20
88	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	3.0	18
89	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	3.8	33
90	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	3.0	24

#	ARTICLE	IF	CITATIONS
91	Safety of systemic treatments for Behçet's syndrome. Expert Opinion on Drug Safety, 2020, 19, 1269-1301.	2.4	6
92	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.9	3
93	Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Multiple Sclerosis and Related Disorders, 2020, 42, 102152.	2.0	14
94	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. Clinical and Experimental Immunology, 2020, 201, 200-204.	2.6	6
95	Peripheral and central nervous system correlates in fibromyalgia. European Journal of Pain, 2020, 24, 1537-1547.	2.8	19
96	Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis. Journal of Scleroderma and Related Disorders, 2020, 5, 210-218.	1.7	1
97	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2090604.	2.7	34
98	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	2.6	21
99	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. Inflammopharmacology, 2020, 28, 711-718.	3.9	19
100	COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatology International, 2020, 40, 827-828.	3.0	33
101	Temporomandibular Disorders and Oral Features in Systemic Lupus Erythematosus Patients: An Observational Study of Symptoms and Signs. International Journal of Medical Sciences, 2020, 17, 153-160.	2.5	15
102	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
103	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine, 2020, 15, 1031-1039.	2.0	13
104	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5.	3.0	20
105	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	15
106	AB0296...EFFECTIVENESS OF CERTOLIZUMAB IN 506 PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND SPONDYLOARTHRITIS FROM THE APULIAN REGISTRY BIOPURE.. Annals of the Rheumatic Diseases, 2020, 79, 1447.2-1447.	0.9	0
107	Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients. Rheumatology, 2020, 59, 1442-1444.	1.9	1
108	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clinical and Experimental Rheumatology, 2020, 38, 19-26.	0.8	5

#	ARTICLE	IF	CITATIONS
109	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.8	6
110	Efficacy of monoclonal anti-tumour necrosis factor- α antibodies in uveitic macular oedema. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 621-625.	0.8	0
111	Thrombocytopenia in idiopathic inflammatory myopathies: a case series analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 891-895.	0.8	2
112	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 925-932.	0.8	0
113	Reply to Praprotnik and Tomsic and erratum corrigé. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1034.	0.8	0
114	Effectiveness of TNF- α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1138-1144.	0.8	4
115	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , 2019, 38, 407-415.	2.2	56
116	Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1256.	2.4	11
117	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1309-1317.	2.2	15
118	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.9	58
119	The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. <i>Reumatismo</i> , 2019, 71, 5-21.	0.9	39
120	Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRATE validation study (INterStitial pneumonia in rheumatoid Arthritis with) Tj ETQq0 0 0 2gBT /Overclock 10 TF	0.9	10
121	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. <i>Rheumatology</i> , 2019, 58, 2221-2229.	1.9	11
122	Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. <i>Muscle and Nerve</i> , 2019, 60, 315-327.	2.2	31
123	How Important Are the Standard Measures in Assessing the Clinical Outcomes in Psoriatic Arthritis in Real-world Settings?. <i>Journal of Rheumatology</i> , 2019, 46, 450-452.	2.0	4
124	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019, 66, 57-61.	2.2	9
125	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
126	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1898.	4.1	60

#	ARTICLE	IF	CITATIONS
127	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
128	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
129	Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?. <i>Clinical Drug Investigation</i> , 2019, 39, 565-575.	2.2	8
130	Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE). <i>Reumatismo</i> , 2019, 71, 24-30.	0.9	6
131	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	3.0	27
132	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1468.	3.5	19
133	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.9	13
134	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. <i>RMD Open</i> , 2019, 5, e000994.	3.8	22
135	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1736-1737.	0.9	21
136	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
137	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. <i>Rheumatology</i> , 2019, 58, 440-440.	1.9	4
138	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	2.0	36
139	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
140	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 719-722.	2.0	13
141	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 34-39.	1.8	37
142	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	3.4	34
143	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , 2019, 38, 63-70.	2.2	29
144	Chondrocytes treated with different shock wave devices. <i>Muscles, Ligaments and Tendons Journal</i> , 2019, 07, 152.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. <i>Indian Journal of Rheumatology</i> , 2019, 14, 271.	0.4	1
146	Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 575-584.	0.8	10
147	Efficacy of anti-tumour necrosis factor-Î± monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 301-305.	0.8	8
148	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.8	10
149	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 680-683.	0.8	19
150	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.8	10
151	Predictors of sustained clinical response in patients with Behçetâ€™s disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , 2018, 37, 1715-1720.	2.2	21
152	Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). <i>Clinical Rheumatology</i> , 2018, 37, 667-675.	2.2	28
153	Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 311-318.	1.1	11
154	Biological therapies for the treatment of Behçetâ€™s disease-related uveitis beyond TNF-alpha blockade: a narrative review. <i>Rheumatology International</i> , 2018, 38, 25-35.	3.0	15
155	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	3.4	9
156	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologicsâ€™ register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	2.2	37
157	Cumulative retention rate of adalimumab in patients with Behçetâ€™s disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , 2018, 102, 637-641.	3.9	44
158	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
159	A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 336-337.	1.1	2
160	OP0142â€¦Rituximab in systemic sclerosis : safety and efficacy data from the eustar network. , 2018, , .		1
161	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	30
162	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2018, 7, 504.	2.4	61

#	ARTICLE	IF	CITATIONS
163	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. <i>RMD Open</i> , 2018, 4, e000809.	3.8	17
164	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	1.9	24
165	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet's disease. <i>Immunology Letters</i> , 2018, 201, 38-44.	2.5	24
166	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258.	5.8	2
167	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	3
168	Orofacial Manifestations and Temporomandibular Disorders of Sjögren Syndrome: An Observational Study. <i>International Journal of Medical Sciences</i> , 2018, 15, 475-483.	2.5	25
169	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , 2018, 37, 2805-2809.	2.2	35
170	Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset. <i>Lupus</i> , 2018, 27, 1479-1488.	1.6	16
171	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	2.2	64
172	Influence of baseline modified Rheumatic Disease Comorbidity Index (<sc>mRDCl</sc>) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13013.	3.4	42
173	FRI0452...Nailfold capillaroscopy in antisynthetase syndrome (NASCAR): results of a multicenter, international study of the american and european network of antisynthetase syndrome (AENEAS). , 2018, , .		0
174	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1276-1282.	0.9	51
175	Possible role of adipocytokines in systemic sclerosis-associated small pericardial effusion. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 153-158.	1.7	0
176	Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e119-e120.	1.2	2
177	Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 105-116.	2.0	37
178	AB0806...The impact of dysphagia in idiopathic inflammatory myositis: an online survey of highly-specialised centres. , 2018, , .		1
179	SAT0223...Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry.. , 2018, , .		0
180	SAT0193...Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
181	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
182	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018, 20, 438-441.	0.1	7
183	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 68-73.	0.8	15
184	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
185	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , 2017, 36, 463-468.	2.2	64
186	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1050-1051.	1.9	31
187	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 103-108.	1.9	22
188	Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. <i>Clinical Drug Investigation</i> , 2017, 37, 375-386.	2.2	14
189	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	5.8	46
190	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.9	150
191	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , 2017, 27, 1031-1035.	1.8	38
192	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 108-114.	3.4	37
193	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017, 36, 2063-2069.	2.2	36
194	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 469-482.	3.0	29
195	IL-6 blockade in the management of non-infectious uveitis. <i>Clinical Rheumatology</i> , 2017, 36, 1459-1469.	2.2	33
196	Polyarthrite rhumatoïde: réponse clinique précoce sous certolizumab prédictive d'une faible activité de la maladie à un an en situation de survie: évaluation du registre italien GISEA. <i>Revue Du Rhumatisme (Edition Française)</i> , 2017, 84, 511-515.	0.0	0
197	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 549-555.	1.4	11
198	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 191-197.	2.2	115

#	ARTICLE	IF	CITATIONS
199	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	2.2	33
200	THU0540...Efficacy and safety of adalimumab in Behçet's disease related uveitis: a multicenter retrospective observational study. , 2017, , .		0
201	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.9	77
202	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
203	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 183-189.	2.2	84
204	Auditory involvement in Behçet's disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , 2017, 36, 445-449.	2.2	9
205	Circulating CD8+CD28^{null} T Cytotoxic Cells in Polymyositisâ€”A Possible Biomarker? Comment on the Article by Pandya et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 243-243.	5.6	0
206	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 451-455.	2.2	52
207	No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 90-96.	1.9	4
208	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
209	Update on the Medical Management of Gastrointestinal Behçet's Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	16
210	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. <i>Frontiers in Immunology</i> , 2017, 8, 200.	4.8	50
211	Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials. <i>Pain Research and Treatment</i> , 2017, 2017, 1-12.	1.7	24
212	A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. <i>American Journal of Case Reports</i> , 2017, 18, 1351-1356.	0.8	28
213	Chondrocytes treated with different shock wave devices. <i>Muscles, Ligaments and Tendons Journal</i> , 2017, 7, 152.	0.3	4
214	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 170-171.	0.8	2
215	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 93-97.	0.8	7
216	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. Israel Medical Association Journal, 2017, 19, 415-419.	0.1	7
218	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 130-131.	0.8	5
219	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	3.5	72
220	A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies. Journal of Clinical Laboratory Analysis, 2016, 30, 859-866.	2.1	22
221	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. Clinical Rheumatology, 2016, 35, 2363-2367.	2.2	22
222	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	2.2	83
223	Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. Joint Bone Spine, 2016, 83, 721-725.	1.6	8
224	Management of Small Vessel Vasculitides. Current Rheumatology Reports, 2016, 18, 36.	4.7	9
225	New therapeutic solutions for Behçet's syndrome. Expert Opinion on Investigational Drugs, 2016, 25, 827-840.	4.1	36
226	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	2.2	28
227	Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. EBioMedicine, 2016, 11, 302-306.	6.1	27
228	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	2.2	19
229	FRI0070...Trajectories of Disease Activity in Rheumatoid Arthritis Patients after Abatacept Initiation and Their Association with Clinical Characteristics. Annals of the Rheumatic Diseases, 2016, 75, 451.2-452.	0.9	0
230	AB0204...Glucocorticoid-Sparing Effects of Abatacept in Rheumatoid Arthritis Are Associated with both Abatacept Effectiveness and Seropositivity. Annals of the Rheumatic Diseases, 2016, 75, 967.1-967.	0.9	0
231	SAT0052...Is Information about The Reason for Previous Biologics Discontinuation Useful To Predict The Effectiveness of A Biologic with A Different Mode of Action?. Annals of the Rheumatic Diseases, 2016, 75, 682.2-682.	0.9	0
232	SAT0384...Long-Term Safety of Anti-Tnf Agents in Patients with Spondyloarthritis and Potential Occult HBV: An Observational Multicenter Study on 131 Patients. Annals of the Rheumatic Diseases, 2016, 75, 807.1-807.	0.9	0
233	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. Journal of International Medical Research, 2016, 44, 28-32.	1.0	5
234	Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis and Rheumatology, 2016, 68, 1346-1352.	5.6	102

#	ARTICLE	IF	CITATIONS
235	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , 2016, 35, 501-505.	2.2	28
236	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , 2016, 15, 447-450.	5.8	54
237	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , 2016, 43, 911-917.	2.0	19
238	Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. <i>Current Rheumatology Reports</i> , 2016, 18, 3.	4.7	55
239	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	2.2	10
240	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	2.2	95
241	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". <i>Clinical Rheumatology</i> , 2016, 35, 839-840.	2.2	1
242	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 424-9.	0.8	11
243	Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 961-962.	0.8	3
244	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 531-8.	0.8	23
245	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 353.	0.8	7
246	Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , 2016, 18, 171-6.	0.1	26
247	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behçet's Disease with Different Organ Involvement: A Case Series. <i>Israel Medical Association Journal</i> , 2016, 18, 238-42.	0.1	18
248	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 77-81.	0.8	21
249	Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1098-1100.	0.8	5
250	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behçet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	1.0	31
251	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 908-912.	1.9	2
252	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M variant. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 473-475.	1.9	5

#	ARTICLE	IF	CITATIONS
253	The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. <i>RMD Open</i> , 2015, 1, e000040-e000040.	3.8	38
254	AB0347â€¦Effects of Physical Activity and Anti-TNF-Alpha Disease Control on Lipid Profile of Rheumatoid Arthritis Patients:. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1009.3-1009.	0.9	0
255	AB0452â€¦Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1046.3-1047.	0.9	0
256	FRIO477â€¦Isolated Arthritis Revealing an Underlying Anti-Synthetase Syndrome: Results from a Multicentre International Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 601.1-601.	0.9	0
257	Safety of longâ€¦term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015, 62, 40-46.	7.3	82
258	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisyndetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
259	Recovery of Barium Swallow Radiographic Abnormalities in a Patient With Dermatomyositis and Severe Dysphagia After High-Dose Intravenous Immunoglobulins. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 227.	0.9	4
260	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. <i>Reumatismo</i> , 2015, 67, 17-20.	0.9	1
261	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	3
262	Influence of TNF-Î± inhibition on oxidative stress of rheumatoid arthritis patients. <i>Reumatismo</i> , 2015, 67, 97-102.	0.9	12
263	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	3.0	41
264	Mucocutaneous Involvement in Behçetâ€™s Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	22
265	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-21.	3.0	79
266	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	1.9	22
267	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , 2015, 94, e1528.	1.0	51
268	Two-year survival rates of anti-TNF-Î± therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 192-199.	1.1	30
269	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. <i>Autoimmunity Reviews</i> , 2015, 14, 503-509.	5.8	150
270	Obesity reduces the drug survival of second line biological drugs following a first TNF-Î± inhibitor in rheumatoid arthritis patients. <i>Joint Bone Spine</i> , 2015, 82, 187-191.	1.6	58

#	ARTICLE	IF	CITATIONS
271	L'efficacité d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition) Tj ETQ, 2015, 1, 0.784314	1.0	1
272	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. <i>Clinical Rheumatology</i> , 2015, 34, 1171-1180.	2.2	15
273	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e70-e70.	0.9	2
274	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
275	Evaluation of differences in carotid intima-media thickness in patients affected by systemic rheumatic diseases. <i>Internal and Emergency Medicine</i> , 2015, 10, 823-830.	2.0	4
276	Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , 2015, 34, 391-395.	2.2	25
277	Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 224-228.	1.1	22
278	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. <i>Autoimmunity Reviews</i> , 2015, 14, 90-97.	5.8	55
279	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015, 14, 1-9.	5.8	79
280	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , 2015, 34, 807-809.	2.2	20
281	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , 2015, 34, 1141-1143.	2.2	51
282	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.8	22
283	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S171-2.	0.8	6
284	Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 524-30.	0.8	2
285	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 688-93.	0.8	18
286	Varicella-zoster virus infection in rheumatoid arthritis patients in the anti-tumour necrosis factor era. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 917-23.	0.8	6
287	AB0380...The Inhibition of Tumor Necrosis Factor-Alpha (TNFA) Reduce Plasmatic Reactive Oxygen Metabolites (ROM) of Rheumatoid Arthritis (RA) Patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 932.1-932.	0.9	0
288	AB0448...Drug Survival of A Patients Cohort with Chronic Inflammatory RHEUMATISM Treated with Abatacept. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 956.2-956.	0.9	0

#	ARTICLE	IF	CITATIONS
289	Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. <i>Reumatismo</i> , 2014, 66, 215-223.	0.9	5
290	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , 2014, 65, 298.	0.9	4
291	Untangling the Web of Systemic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	3.0	25
292	SAT0302â€¦Does MRI Have an Added Value over CK in Assessing Disease Activity in the Idiopathic Inflammatory Myopathies?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 702.1-702.	0.9	0
293	Lipid Profile of Rheumatoid Arthritis Patients Treated with Antiâ€Tumor Necrosis Factorâ€Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. <i>Drug Development Research</i> , 2014, 75, S77-80.	2.9	13
294	Retinal Vessels Thrombosis as Onset Manifestation of Systemic Sclerosis: 3 Clinical Cases. <i>Journal of Rheumatology</i> , 2014, 41, 2495-2496.	2.0	5
295	HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-9.	1.6	57
296	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	2.2	10
297	Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. <i>Journal of Neurology</i> , 2014, 261, 461-472.	3.6	61
298	Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial. <i>Journal of Rheumatology</i> , 2014, 41, 286-292.	2.0	47
299	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
300	Drug survival on TNF inhibitors: 2003â€2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e31-e31.	0.9	8
301	Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations. <i>Journal of rheumatology Supplement</i> , The, 2014, 91, 41-46.	2.2	61
302	Serum amyloid-A in Behçetâ€™s disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	2.2	14
303	Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. <i>BMC Research Notes</i> , 2014, 7, 316.	1.4	14
304	Different switching rate of anti-TNF- α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , 2014, 81, 458-459.	1.6	6
305	Key facts and hot spots on tumor necrosis factor receptorâ€associated periodic syndrome. <i>Clinical Rheumatology</i> , 2014, 33, 1197-1207.	2.2	58
306	FRIO322â€¦Positivity for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide is Associated with A Better Drug Retention of Abatacept: Data from A Paneuropean Analysis of RA Registries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 502.2-503.	0.9	5

#	ARTICLE	IF	CITATIONS
307	SAT0571â€¦Role of Obesity in the Expression of Cytokines and Metalloproteinases in Human Osteoarthritis Chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 797.1-797.	0.9	1
308	Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-Î± therapy. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 41-44.	1.1	29
309	FRI0255â€¦Evaluation of early markers of cardiovascular risk in subjects affected by systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 400.2-400.	0.9	0
310	The Inhibitor of Costimulation of T Cells: Abatacept. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 100-102.	2.2	29
311	Longterm Retention of Tumor Necrosis Factor-Î± Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	2.0	87
312	Bosentan fosters microvascular de-remodelling in systemic sclerosis. <i>Clinical Rheumatology</i> , 2012, 31, 1723-1725.	2.2	50
313	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
314	Chemerin/ChemR23 pathway: a system beyond chemokines. <i>Arthritis Research and Therapy</i> , 2011, 13, 104.	3.5	28
315	Is there a role for TNFÎ± antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S40-5.	0.8	57
316	Obesity and Inflammation â€œ Targets for OA Therapy. <i>Current Drug Targets</i> , 2010, 11, 586-598.	2.1	82
317	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
318	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
319	Digital laser doppler flowmetry may discriminate â€œlimitedâ€œ from â€œdiffuseâ€œ systemic sclerosis. <i>Microvascular Research</i> , 2010, 80, 221-226.	2.5	15
320	Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis. <i>Laboratory Medicine</i> , 2009, 40, 645-650.	1.2	1
321	Extracorporeal shock waves increase interleukin-10 expression by human osteoarthritic and healthy osteoblasts in vitro. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 794-9.	0.8	5
322	Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 16.	1.9	38
323	Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1121-1126.	0.9	55
324	Phenotype of chondrocytes in osteoarthritis. <i>Biorheology</i> , 2008, 45, 411-413.	0.4	9

#	ARTICLE	IF	CITATIONS
325	Phenotype of chondrocytes in osteoarthritis. <i>Biorheology</i> , 2008, 45, 411-3.	0.4	4
326	Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. <i>European Journal of Clinical Investigation</i> , 2006, 36, 73-77.	3.4	10
327	Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset. <i>Clinical Rheumatology</i> , 2006, 25, 919-922.	2.2	4
328	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.9	46
329	Use of etanercept in the treatment of dermatomyositis: a case series. <i>Journal of Rheumatology</i> , 2006, 33, 1802-4.	2.0	82
330	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. <i>Arthritis and Rheumatism</i> , 2005, 52, 2519-2520.	6.7	48
331	Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 217-221.	0.9	29
332	The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. <i>Current Medical Research and Opinion</i> , 2005, 21, 327-332.	1.9	43
333	Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. <i>Journal of Rheumatology</i> , 2005, 32, 1893-8.	2.0	6
334	Metabolic Activity of Chondrocytes in Human Osteoarthritis as a Result of Cell-extracellular Matrix Interactions. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 9-12.	3.4	7
335	The pathophysiology of osteoarthritis. <i>Ageing Clinical and Experimental Research</i> , 2003, 15, 364-372.	2.9	153
336	Leucocytoclastic vasculitis as onset symptom of ulcerative colitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 785-786.	0.9	28
337	Microscopic polyangiitis associated with primary biliary cirrhosis. <i>Journal of Rheumatology</i> , 2003, 30, 2710-2.	2.0	17
338	Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. <i>British Journal of Rheumatology</i> , 2002, 41, 1413-1418.	2.3	125
339	Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes. <i>Clinical and Experimental Rheumatology</i> , 2001, 19, 139-45.	0.8	49
340	Chondrocyte phenotyping in human osteoarthritis. <i>Clinical Rheumatology</i> , 1998, 17, 99-104.	2.2	33
341	Neuropeptides and human osteoarthritis. <i>Journal of Rheumatology</i> , 1998, 25, 386-8.	2.0	9
342	Isolated thrombocytopenia associated with low dose methotrexate therapy. <i>Clinical Rheumatology</i> , 1997, 16, 429-430.	2.2	9

#	ARTICLE	IF	CITATIONS
343	Integrin expression on chondrocytes: correlations with the degree of cartilage damage in human osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 1997, 15, 247-54.	0.8	25
344	T-LYMPHOCYTE IMMUNOPHENOTYPING IN POLYMYOSITIS AND DERMATOMYOSITIS. <i>Rheumatology</i> , 1996, 35, 839-845.	1.9	39
345	Expression of membrane-bound peptidases (CD10 and CD26) on human articular chondrocytes. Possible role of neuropeptidases in the pathogenesis of osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 1995, 13, 143-8.	0.8	9
346	Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. <i>European Journal of Immunology</i> , 1994, 24, 2706-2713.	2.9	72
347	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
348	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	3
349	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients with Rheumatoid Arthritis (the MITRA study). A cohort study of the I. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0
350	Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3259-3267.	3.5	0
351	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
352	A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6